TW EN

scroll

Go Top

臺中榮民總醫院 臨床試驗中心Taichung Veterans General Hospital Clinical Trials Center

  • 病床總數1,622
  • 醫師人數934
  • 地址407臺中市西屯區臺灣大道四段1650號研究大樓3樓315B室
  • 電話04-23592525#4780

1. 智慧醫療和試驗分散式系統

2. 細胞治療與創新醫療技術的發展

3. 從研究發展到落地應用的全面性學術支援

臨床試驗中心簡介

臺中榮民總醫院 (TCVGH) 臨床試驗中心建立於2009年,並於2024獲準成為國家級卓越臨床試驗中心。透過最高的道德和科學標準,以尖端的資通技術、專業學術支援的方式推動臨床研究,促進醫療新發現和確效驗證。
我們致力於
(1) 促進行業贊助商和 TVGCH研究者之間的溝通管道;
(2) 提供臨床試驗的基礎設施(研究者和設施);
(3) 聯合同儕卓越臨床試驗中心夥伴與以及其他醫療中心召集IRB聯盟;
(4)促進與學術機構和業界夥伴之國際合作;
(5) 與衛生福利部「臨床試驗新型態卓越計畫」的良好溝通。
台灣以其在醫學、生物科技和資通技術方面的巨大潛力給世界留下深刻印象。 未來,尋求學術醫療中心來驗證新診斷和療法的國內和國際製藥公司、政府研究機構和私營機構,將發現 TVGCH 已將自己置於臨床試驗和研究新型態的頂端。

臨床試驗重點領域

所有重要器官系統之疾病之臨床試驗

國際認證

美國臨床研究受試者保護評鑑協會AAHRPP認證(Full Reaccreditation)
FERCAP國際認證
美國醫療資訊暨管理系統協會(HIMSS)Stage 7 認證

GCP查核

US FDA
Taiwan FDA

卓越亮點

CTC























近年文獻發表

CTC

1

Hickish, T., Mehta, A., Liu, M. C., Huang, C. S., Arora, R. S., Chang, Y. C., Yang, Y., Vladimirov, V., Jain, M., Tsang, J., Pemberton, K., Sadrolhefazi, B., Jin, X., & Tseng, L. M. (2022). Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast cancer research and treatment, 192(3), 593–602. https://doi.org/10.1007/s10549-021-06449-4

2

Lin, S. F., Hu, H. H., Chao, H. L., Ho, B. L., Chen, C. H., Chan, L., Lin, H. J., Sun, Y., Lin, Y. Y., Chen, P. L., Lin, S. K., Wei, C. Y., Lin, Y. T., Lee, J. T., & Chao, A. C. (2022). Triglyceride-Glucose Index and Intravenous Thrombolysis Outcomes for Acute Ischemic Stroke: A Multicenter Prospective-Cohort Study. Frontiers in neurology, 13, 737441. https://doi.org/10.3389/fneur.2022.737441

3

Chen, J. Y., Chen, Y. Y., Pan, H. C., Hsieh, C. C., Hsu, T. W., Huang, Y. T., Huang, T. M., Shiao, C. C., Huang, C. T., Kashani, K., & Wu, V. C. (2022). Accelerated versus watchful waiting strategy of kidney replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomized clinical trials. Clinical kidney journal, 15(5), 974–984. https://doi.org/10.1093/ckj/sfac011

4

Lee, C. T., Lee, C. C., Wu, M. J., Chiu, Y. W., Leu, J. G., Wu, M. S., Peng, Y. S., Wu, M. S., & Tarng, D. C. (2022). Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial. PloS one, 17(3), e0264727. https://doi.org/10.1371/journal.pone.0264727

5

Cheng, Y. Y., Lin, S. Y., Hsu, C. Y., & Fu, P. K. (2022). Respiratory Muscle Training Can Improve Cognition, Lung Function, and Diaphragmatic Thickness Fraction in Male and Non-Obese Patients with Chronic Obstructive Pulmonary Disease: A Prospective Study. Journal of personalized medicine, 12(3), 475. https://doi.org/10.3390/jpm12030475

6

Chen, J. Y., Chen, Y. Y., Pan, H. C., Hsieh, C. C., Hsu, T. W., Huang, Y. T., Huang, T. M., Shiao, C. C., Huang, C. T., Kashani, K., & Wu, V. C. (2022). Accelerated versus watchful waiting strategy of kidney replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomized clinical trials. Clinical kidney journal, 15(5), 974–984. https://doi.org/10.1093/ckj/sfac011

7

Cukierman-Yaffe, T., Gerstein, H. C., Basile, J., Bethel, M. A., Cardona-Muñoz, E. G., Conget, I., Dagenais, G., Franek, E., Hall, S., Hancu, N., Jansky, P., Lakshmanan, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Pirags, V., Pogosova, N., Probstfield, J., Rao-Melacini, P., Ramasundarahettige, C., … Temelkova-Kurktschiev, T. (2022). Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. The Journal of clinical endocrinology and metabolism, 107(8), e3448–e3454. https://doi.org/10.1210/clinem/dgac200

8

Shih, M. Y., & Chen, C. (2022). Letter to the Editor with Reference to "The Efficacy and Safety of Topical β-Blockers in Treating Infantile Hemangiomas: A Meta-Analysis Including 11 Randomized Controlled Trials". Dermatology (Basel, Switzerland), 238(6), 1152–1153. https://doi.org/10.1159/000524531

9

Nguyen, T. T., Chiu, C. H., Lin, C. Y., Chiu, N. C., Chen, P. Y., Le, T. T. V., Le, D. N., Duong, A. H., Nguyen, V. L., Huynh, T. N., Truong, H. K., Phan, T. L., Nguyen, T. T. T., Shih, S. R., Huang, C. G., Weng, Y. J., Hsieh, E. F., Chang, S., Chen, C., Tai, I. C., … Huang, L. M. (2022). Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet (London, England), 399(10336), 1708–1717. https://doi.org/10.1016/S0140-6736(22)00313-0

10

Tung, R., Xue, Y., Chen, M., Jiang, C., Shatz, D. Y., Besser, S. A., Hu, H., Chung, F. P., Nakahara, S., Kim, Y. H., Satomi, K., Shen, L., Liang, E., Liao, H., Gu, K., Jiang, R., Jiang, J., Hori, Y., Choi, J. I., Ueda, A., … PAUSE-SCD Investigators (2022). First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation, 145(25), 1839–1849. https://doi.org/10.1161/CIRCULATIONAHA.122.060039